Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25081617 | 0.94 | MDM4 (0.42) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL25081912 | 0.93 | MDM4 (0.49) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL25081616 | 0.91 | MDM2 (0.44) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL29402061 | 0.80 | MDM4 (0.54) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL29398288 | 0.80 | MDM4 (0.54) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL30389933 | 0.79 | ACE (0.42) | MDM4TP53MDM2SLC17A5 | |
| SCHEMBL29238562 | 0.79 | ACE (0.42) | MDM4TP53MDM2SLC17A5 | |
| SCHEMBL31647183 | 0.78 | MDM2 (0.56) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL13863441 | 0.76 | KMT2A (0.53) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL10028351 | 0.76 | KMT2A (0.53) | MDM4TP53MDM2CASP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391873-A1 | PROCESS FOR THE PREPARATION OF PEGYLATED ADRENOMEDULLIN, ITS INTERMEDIATES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-11-28 | — | — | US | disclosed |
| CN-117957021-A | Process for preparing pegylated adrenomedullin, intermediates therefor and uses thereof | 拜耳公司 | 2024-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391873-A1 | PROCESS FOR THE PREPARATION OF PEGYLATED ADRENOMEDULLIN, ITS INTERMEDIATES AND USE THEREOF | ADM2, HAMP, SERPINC1 | MDM4 4599/4885TP53 4038/4885MDM2 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.